Cargando…

Dasatinib in chronic myeloid leukemia: a review

Deregulated BCR-ABL tyrosine kinase (TK) activity is the molecular marker for chronic myeloid leukemia (CML), which provides an identifiable target for developing therapeutic agents. Imatinib mesylate, a BCR-ABL TK inhibitor, is the frontline therapy for CML. Despite the stunning efficacy of this ag...

Descripción completa

Detalles Bibliográficos
Autores principales:	Aguilera, Dolly G, Tsimberidou, Apostolia M
Formato:	Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2009
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2697539/ https://www.ncbi.nlm.nih.gov/pubmed/19536317

Ejemplares similares

Systematic review of dasatinib in chronic myeloid leukemia
por: Breccia, Massimo, et al.
Publicado: (2013)

The role of dasatinib in the management of chronic myeloid leukemia
por: Chen, Runzhe, et al.
Publicado: (2015)

Efficacy of dasatinib for the treatment of intractable chronic myeloid leukemia
por: Lima, Lisa M, et al.
Publicado: (2010)

Dasatinib dose management for the treatment of chronic myeloid leukemia
por: Talpaz, Moshe, et al.
Publicado: (2018)

Targeted treatment of imatinib-resistant chronic myeloid leukemia: Focus on dasatinib
por: Chuah, Charles, et al.
Publicado: (2009)

First-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib
por: Wei, Guoqing, et al.
Publicado: (2010)

Dasatinib for the treatment of chronic myeloid leukemia: patient selection and special considerations
por: Keskin, Dilek, et al.
Publicado: (2016)

Dasatinib in the treatment of imatinib refractory chronic myeloid leukemia
por: Ramchandren, Radhakrishnan, et al.
Publicado: (2009)

Dasatinib: the emerging evidence of its potential in the treatment of chronic myeloid leukemia
por: Haslam, Sonya
Publicado: (2005)

What Is the Optimal Dose and Schedule for Dasatinib in Chronic Myeloid Leukemia: Two Case Reports and Review of the Literature
por: Jamison, Caroline, et al.
Publicado: (2016)

Reversible Pulmonary Arterial Hypertension Associated with Dasatinib for Chronic Myeloid Leukemia
por: Hong, Ji Hyung, et al.
Publicado: (2015)

Skin lesions in chronic myeloid leukemia patients during dasatinib treatment
por: Tarantini, Francesco, et al.
Publicado: (2019)

Diagnostic Pitfalls of Chylothorax After Dasatinib Treatment of Chronic Myeloid Leukemia
por: Kelly, Ryan L., et al.
Publicado: (2022)

Dasatinib-Induced Colitis with Rectal Sparing in a Patient with Chronic Myeloid Leukemia (Chronic Phase) on Dasatinib as an Upfront Therapy: Case Report
por: Maat, Zakaria, et al.
Publicado: (2021)

Optic neuropathy secondary to dasatinib in the treatment of a chronic myeloid leukemia case
por: Monge, Katia Sotelo, et al.
Publicado: (2015)

Dasatinib-induced massive left chylothorax in a patient with chronic myeloid leukemia
por: Makimoto, Go, et al.
Publicado: (2022)

Dasatinib - clinical trials and management of adverse events in imatinib resistant/intolerant chronic myeloid leukemia
por: Conchon, Monika, et al.
Publicado: (2011)

Treatment-free remission after discontinuation of imatinib, dasatinib, and nilotinib in patients with chronic myeloid leukemia
por: Han, Jae Joon
Publicado: (2023)

Lymphocytosis after treatment with dasatinib in chronic myeloid leukemia: Effects on response and toxicity
por: Schiffer, Charles A., et al.
Publicado: (2016)

Insights into dasatinib use and outcomes in real-world patients with chronic myeloid leukemia
por: Adattini, Josephine A., et al.
Publicado: (2023)

Expanding dasatinib beyond KIT in acute myeloid leukemia
por: Welch, John S.
Publicado: (2020)

Successful Pregnancy and Delivery in a Patient with Chronic Myeloid Leukemia while on Dasatinib Therapy
por: Conchon, Monika, et al.
Publicado: (2010)

Efficacy and Tolerability after Unusually Low Doses of Dasatinib in Chronic Myeloid Leukemia Patients Intolerant to Standard-Dose Dasatinib Therapy
por: Serpa, Mariana, et al.
Publicado: (2010)

Dasatinib Induced Avascular Necrosis of Femoral Head in Adult Patient with Chronic Myeloid Leukemia
por: Yassin, Mohamed A, et al.
Publicado: (2015)

Dasatinib associated lymphadenopathy in a chronic myeloid leukemia patient: A case report
por: Pilalas, Dimitrios, et al.
Publicado: (2020)

IFN-α with dasatinib broadens the immune repertoire in patients with chronic-phase chronic myeloid leukemia
por: Huuhtanen, Jani, et al.
Publicado: (2022)

Dasatinib-Induced Rhabdomyolysis in a 33-Year-Old Patient with Chronic Myeloid Leukemia
por: Joel Chandranesan, Andrew Stevenson, et al.
Publicado: (2018)

Primary Effusion Lymphoma in an HIV-Negative Patient with Chronic Myeloid Leukemia Treated with Dasatinib
por: SahBandar, Ivo N., et al.
Publicado: (2023)

Dasatinib-Induced Hypopigmentation in Pediatric Patient with Chronic Myeloid Leukemia: A Case Report and Review of the Literature
por: Alharbi, Bader, et al.
Publicado: (2018)

The development of dasatinib as a treatment for chronic myeloid leukemia (CML): from initial studies to application in newly diagnosed patients
por: Hochhaus, Andreas, et al.
Publicado: (2013)

Interstitial pneumonitis associated with dasatinib treatment for chronic myeloid leukemia or acute lymphoblastic leukemia: case series and a literature review
por: Kim, Sang-A, et al.
Publicado: (2022)

Dasatinib-associated chylothorax in a pediatric patient with chronic myeloid leukemia: a case report and literature review
por: Liu, Qinqin, et al.
Publicado: (2023)

Cytomegalovirus-induced Hemorrhagic Colitis in a Patient with Chronic Myeloid Leukemia (Chronic Phase) on Dasatinib as an Upfront Therapy
por: Yassin, Mohamed A, et al.
Publicado: (2015)

Isolated central nervous system blast crisis in a case of chronic myeloid leukemia on dasatinib
por: Kiran, P. K., et al.
Publicado: (2018)

Dasatinib-Associated Acneiform Eruption Successfully Treated With Sarecycline in a Patient With Chronic Myeloid Leukemia
por: Poplausky, Dina, et al.
Publicado: (2023)

Erythema nodosum following treatment with dasatinib plus chemotherapy in a patient with myeloid blast phase of chronic myeloid leukemia
por: Kassem, Nancy, et al.
Publicado: (2023)

Long lasting complete molecular remission after suspending dasatinib treatment in chronic myeloid leukemia
por: Gadó, Klára, et al.
Publicado: (2012)

Clinical significance of dasatinib-induced pleural effusion in patients with de novo chronic myeloid leukemia
por: Nakaya, Aya, et al.
Publicado: (2018)

Effects of dasatinib on CD8(+)T, Th1, and Treg cells in patients with chronic myeloid leukemia
por: Wei, Xiaoqing, et al.
Publicado: (2019)

Variables associated with pulmonary hypertension screened by echocardiography in chronic myeloid leukemia patients on dasatinib therapy
por: Jin, Wenying, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_orgjdd29pqeuhf4rbf5ue0kbcj